logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Ironwood Pharmaceuticals, Inc.

Calculating rank
USPTO Granted Patents = 44

% Expired Patents = 27.3



Trademarks = 13

Forward Citations = 322

Loading Chart...
Loading Chart...

67 inventors (with patents filed for the assignee):

goldMedal Mark G Currie (24 out of 70 patents)

silverMedal Angelika Fretzen (18 out of 21 patents)

bronzeMedal Takashi Nakai (10 out of 23 patents)

4.  Joel D Moore (10 out of 27 patents)

5.  Nicholas Robert Perl (9 out of 19 patents)

6.  Ara Mermerian (9 out of 18 patents)

7.  G Todd Milne (9 out of 16 patents)

8.  Shalina Mahajan-Miklos (9 out of 11 patents)

9.  Rajesh R Iyengar (8 out of 26 patents)

10.  Timothy Claude Barden (8 out of 19 patents)

11.  Daniel P Zimmer (8 out of 10 patents)

12.  Thomas Wai-Ho Lee (7 out of 17 patents)

13.  Marco Kessler (7 out of 9 patents)

14.  Charles Kim (7 out of 7 patents)

15.  Thea Norman (6 out of 39 patents)


Core Competencies:
Linaclotide
Gastrointestinal Disorders
sGC Stimulators
FAAH Inhibitors
Indole Compounds
Polymorphs
Bile Acid Sequestrants
Heart Failure
Asthma
Anxiolytic Compounds
Imidazotriazinone
CRTH2 Modulators

44 patents:

1. 10702576 - Stable formulations of linaclotide (2020-07-07),
2. 10675325 - Stable formulations of linaclotide (2020-06-09),
3. 10618938 - Compositions for colon cleansing and the treatment of gastrointestinal disorders (2020-04-14),
4. 10266529 - Salts, co-crystals, and polymorphs of an anxiolytic compound (2019-04-23),
5. 10189809 - SGC stimulators (2019-01-29),
6. 10183021 - sGC stimulators (2019-01-22),
7. 10047095 - sGC stimulators (2018-08-14),
8. 9969742 - Imidazotriazinone compounds (2018-05-15),
9. 9840536 - Methods and compositions for the treatment of gastrointestinal disorders (2017-12-12),
10. 9745296 - Salts, co-crystals, and polymorphs of an anxiolytic compound (2017-08-29),
11. 9725453 - Imidazotriazinone compounds (2017-08-08),
12. 9708371 - Treatments for gastrointestinal disorders (2017-07-18),
13. 9657012 - FAAH inhibitors (2017-05-23),
14. 9650417 - Treatments for gastrointestinal disorders (2017-05-16),
15. 9617305 - Treatments for gastrointestinal disorders (2017-04-11),
Company Overview
Ironwood Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, MA, specializing in the development of innovative therapies for gastrointestinal disorders. The company is known for its work with linaclotide, a treatment for irritable bowel syndrome, and is actively engaged in research on sGC stimulators and FAAH inhibitors. Ironwood's portfolio also includes compounds targeting asthma and other conditions, reflecting its commitment to addressing unmet medical needs through advanced therapeutic solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Ironwood Pharmaceuticals, Inc. USPTO Patent Assignee Logo
44 Patents

#65 in Cambridge, MA

#456 in Massachusetts

#7,963 in US

#15,771 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Ironwood Pharmaceuticals, Inc.

Forward Citations = 322

67 inventors:

goldMedal Mark G Currie (24 out of 70 patents)

silverMedal Angelika Fretzen (18 out of 21 patents)

bronzeMedal Takashi Nakai (10 out of 23 patents)

4.  Joel D Moore (10 out of 27 patents)

5.  Nicholas Robert Perl (9 out of 19 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ironwood Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/ironwood-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…